The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

Scott D. Solomon; Michael R. Zile; Burkert Pieske; Adriaan A. Voors; Amil M. Shah; Elisabeth Kraigher‐Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Marty Lefkowitz; Milton Packer; John J.V. McMurray

doi:10.1016/s0140-6736(12)61227-6

Keywords

NeprilysinEjection fractionHeart failureMedicineDouble blindCardiologyAngiotensin receptorInternal medicineSacubitrilPharmacologyAngiotensin IIReceptorChemistryPlaceboPathology

Affiliated Institutions

Related Publications

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Jessie Gu , Adele Noè , Priya Chandra +10 more

Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single mol...

2009 The Journal of Clinical Pharmacology 491 citations

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

John J.V. McMurray , Milton Packer , Akshay S. Desai +8 more

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone sys...

2013 European Journal of Heart Failure 439 citations

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances

John J.V. McMurray

This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degradation of natriuretic and other vasoactive peptides, including br...

2015 European Journal of Heart Failure 121 citations

Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)

John J.V. McMurray , Milton Packer , Akshay S. Desai +8 more

Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global ...

2014 European Journal of Heart Failure 167 citations

Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

James B. Young , Mark E. Dunlap , Marc A. Pfeffer +15 more

Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...

2004 Circulation 393 citations

Publication Info

Year: 2012
Type: article
Volume: 380
Issue: 9851
Pages: 1387-1395
Citations: 1142
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1142

OpenAlex

Cite This

APA Style

                            
                                
                                    Scott D. Solomon, 
                                
                                    Michael R. Zile, 
                                
                                    Burkert Pieske
                                
                                et al.
                            
                            (2012). 
                            The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. 
                            The Lancet
                            , 380
                            (9851)
                            , 1387-1395.
                            https://doi.org/10.1016/s0140-6736(12)61227-6
                        

Identifiers

DOI: 10.1016/s0140-6736(12)61227-6